Recombinant human histone H1.3

Drug Profile

Recombinant human histone H1.3

Alternative Names: OncoHist; Product F - SymbioTec; rhH1.3; SYN-20051504RU; SYN-20051604RU

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator SymbioTec
  • Developer Dana-Farber Cancer Institute; Pharmsynthez; SymbioTec; Xenetic Biosciences
  • Class Antineoplastics; Biological proteins; Recombinant proteins
  • Mechanism of Action Apoptosis stimulants; Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Acute lymphoblastic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
  • 05 Oct 2016 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Russia (IV) (Xenetic Biosciences pipeline, October 2016)
  • 05 Oct 2016 Phase-II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Russia (IV) (Xenetic Biosciences pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top